Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

79.50CHF
24 May 2017
Change (% chg)

CHF0.20 (+0.25%)
Prev Close
CHF79.30
Open
CHF79.10
Day's High
CHF80.00
Day's Low
CHF78.85
Volume
64,187
Avg. Vol
76,162
52-wk High
CHF95.35
52-wk Low
CHF61.20

Latest Key Developments (Source: Significant Developments)

Basilea shareholders approve resolutions proposed by the board at the general meeting of shareholders
Thursday, 27 Apr 2017 12:32pm EDT 

April 27 (Reuters) - Basilea Pharmaceutica Ag :Basilea shareholders approve all resolutions proposed by the board of directors at the ordinary general meeting of shareholders.Shareholders also approved increase of authorized share capital..Basilea says shareholders elected Dr. Nicole Onetto as new member of board and re-elected Domenico Scala as chairman.  Full Article

Basilea Pharmaceutica: agreement with FDA regarding ceftobiprole
Friday, 21 Apr 2017 01:16am EDT 

April 21 (Reuters) - Basilea Pharmaceutica AG ::Basilea announces agreement with FDA on special protocol assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections.Initiation of ceftobiprole pivotal phase 3 clinical program under barda contract anticipated within next three to six months.  Full Article

Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million
Monday, 20 Feb 2017 01:15am EST 

Basilea Pharmaceutica AG : In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study . Product sales of 7.1 million Swiss francs ($7.08 million) in europe and 7.3 million francs royalties received on 2016 Cresemba US sales . 289 million francs cash and financial investments at 2016 year-end . FY net loss 51.3 million francs versus 61.6 million francs year ago .Sales for 2016 full year of 7.1 million francs in Europe.  Full Article

MedCap unit to distribute Basilea's products in Scandinavia
Tuesday, 20 Sep 2016 02:38am EDT 

MedCap AB (publ) : Says its unit Unimedic Pharma AB has entered into licensing and distribution agreement with Basilea Pharmaceutica Ltd .Agreement is for distribution of Basilea's products in Sweden, Denmark, Norway and Finland.  Full Article

Basilea Pharmaceutica: distribution agreement with Hikma for Cresemba in MENA region
Wednesday, 17 Aug 2016 01:15am EDT 

Basilea Pharmaceutica AG :Basilea announces distribution agreement with Hikma for Cresemba (isavuconazole) in the MENA region.  Full Article

Basilea Pharmaceutica H1 net loss narrows to CHF 27.9 million
Monday, 15 Aug 2016 01:15am EDT 

Basilea Pharmaceutica AG : Contract revenue in first half-year of 2016 amounted to 27.8 million Swiss francs ($28.50 million) (H1 2015: 24.4 million francs) . In H1 2016, operating loss amounted to 24.8 million francs, compared to 30.0 million francs in H1 2015 . H1 2016 product revenue amounted to 1.9 million francs (H1 2015: 0 million francs) . Total operating income in H1 2016 including sales amounted to 29.7 million francs (H1 2015: 25.0 million francs) . H1 net loss amounted to 27.9 million francs (H1 2015: 30.1 million francs) .Confirms guidance for total operating expenses for 2016 of approximately 9 - 10 million francs on average per month and average operating loss in 2016 of approximately 4 - 5 million francs per month.  Full Article

Basilea Pharmaceutica: CRESEMBA (isavuconazole) launched in Italy
Monday, 27 Jun 2016 01:15am EDT 

Basilea Pharmaceutica AG :Basilea's antifungal CRESEMBA (isavuconazole) launched in Italy.  Full Article

Basilea Pharmaceutica presents data on clinical oncology programs BAL101553 and BAL3833
Thursday, 21 Apr 2016 01:15am EDT 

Basilea Pharmaceutica AG:Reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting.Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment.PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models.  Full Article

Basilea Pharmaceutica wins contract by BARDA of up to $100 mln funding for Ceftobiprole phase 3 program
Wednesday, 20 Apr 2016 01:15am EDT 

Basilea Pharmaceutica AG:Basilea awarded contract by BARDA of up to $100 million funding for Ceftobiprole phase 3 program.  Full Article

Basilea Pharmaceutica nominates Domenico Scala as new chairman of board​
Tuesday, 15 Mar 2016 02:15am EDT 

Basilea Pharmaceutica AG:Martin Nicklasson has determined not to stand for re-election as chairman but will stand for re-election as member of board.​Domenico Scala nominated as new chairman of board​.  Full Article

More From Around the Web

BRIEF-Basilea shareholders approve resolutions proposed by the board at the general meeting of shareholders

* Basilea shareholders approve all resolutions proposed by the board of directors at the ordinary general meeting of shareholders